Ahmad S, Xing K, Rajakaruna H, Stewart W, Beckwith K, Nayak I
bioRxiv. 2025; .
PMID: 39803543
PMC: 11722217.
DOI: 10.1101/2024.12.31.630941.
Almotiri A
Saudi Med J. 2024; 45(10):1007-1019.
PMID: 39379118
PMC: 11463564.
DOI: 10.15537/smj.2024.45.10.20240330.
Gao C, Li X, Xu Y, Zhang T, Zhu H, Yao D
J Cell Mol Med. 2024; 28(9):e18369.
PMID: 38712978
PMC: 11075639.
DOI: 10.1111/jcmm.18369.
Boucher J, Shrestha B, Vishwasrao P, Leick M, Cervantes E, Ghafoor T
Mol Ther Oncolytics. 2023; 31:100751.
PMID: 38075241
PMC: 10701585.
DOI: 10.1016/j.omto.2023.100751.
Dao T, Xiong G, Mun S, Meyerberg J, Korontsvit T, Xiang J
Blood. 2023; 143(6):507-521.
PMID: 38048594
PMC: 10950474.
DOI: 10.1182/blood.2023021054.
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.
Morse J, Rios M, Ye J, Rios A, Zhang C, Daver N
Expert Opin Investig Drugs. 2023; 32(2):107-125.
PMID: 36762937
PMC: 10031751.
DOI: 10.1080/13543784.2023.2179482.
Oncology stewardship in acute myeloid leukemia.
Ochs M, Marini B, Perissinotti A, Foucar C, Pettit K, Burke P
Ann Hematol. 2022; 101(8):1627-1644.
PMID: 35618780
DOI: 10.1007/s00277-022-04872-1.
Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells.
Robida P, Rische C, Ben-Baruch Morgenstern N, Janarthanam R, Cao Y, Krier-Burris R
Cells. 2022; 11(7).
PMID: 35406705
PMC: 8997871.
DOI: 10.3390/cells11071138.
Emerging CAR T Cell Strategies for the Treatment of AML.
Vishwasrao P, Li G, Boucher J, Smith D, Hui S
Cancers (Basel). 2022; 14(5).
PMID: 35267549
PMC: 8909045.
DOI: 10.3390/cancers14051241.
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
Richards R, Zhao F, Freitas K, Parker K, Xu P, Fan A
Blood Cancer Discov. 2021; 2(6):648-665.
PMID: 34778803
PMC: 8580619.
DOI: 10.1158/2643-3230.BCD-20-0208.
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
Gottardi M, Simonetti G, Sperotto A, Nappi D, Luserna di Rora A, Padella A
Cancers (Basel). 2021; 13(18).
PMID: 34572794
PMC: 8469571.
DOI: 10.3390/cancers13184566.
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes J, de Lima M, Dombret H, Estey E, Giralt S, Montesinos P
J Hematol Oncol. 2020; 13(1):137.
PMID: 33059764
PMC: 7559451.
DOI: 10.1186/s13045-020-00975-2.
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S
Int J Mol Sci. 2020; 21(16).
PMID: 32781546
PMC: 7460695.
DOI: 10.3390/ijms21165626.
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K
Blood Adv. 2020; 4(5):906-919.
PMID: 32150609
PMC: 7065489.
DOI: 10.1182/bloodadvances.2019001188.
Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).
Mitchell K, Steidl U
Cold Spring Harb Perspect Med. 2019; 10(1).
PMID: 31451539
PMC: 6938655.
DOI: 10.1101/cshperspect.a036251.
Radiopharmaceuticals for Relapsed or Refractory Leukemias.
Kunos C, Capala J, Ivy S
Front Oncol. 2019; 9:97.
PMID: 30859091
PMC: 6397856.
DOI: 10.3389/fonc.2019.00097.
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
Hofmann S, Schubert M, Wang L, He B, Neuber B, Dreger P
J Clin Med. 2019; 8(2).
PMID: 30736352
PMC: 6406805.
DOI: 10.3390/jcm8020200.
Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
Ma H, Sawas A
Curr Hematol Malig Rep. 2018; 13(6):555-569.
PMID: 30362019
DOI: 10.1007/s11899-018-0485-3.
The expansion of targetable biomarkers for CAR T cell therapy.
Townsend M, Shrestha G, Robison R, ONeill K
J Exp Clin Cancer Res. 2018; 37(1):163.
PMID: 30031396
PMC: 6054736.
DOI: 10.1186/s13046-018-0817-0.
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S, Perna F, Kohnke T, Schmidt C, Berman S, Augsberger C
Leukemia. 2018; 33(1):64-74.
PMID: 29946192
PMC: 6326956.
DOI: 10.1038/s41375-018-0180-3.